Posted by Michael Wonder on 28 Jun 2021
UCB receives positive CHMP opinion recommending approval of Bimzelx (bimekizumab) in the EU for the treatment of adults with moderate to severe plaque psoriasis
25 June 2021 - The positive CHMP opinion is supported by data from three Phase 3 trials where bimekizumab demonstrated superior levels of skin clearance compared to placebo, ustekinumab and adalimumab.
UCB announced today that the EMA's CHMP has adopted a positive opinion recommending granting a marketing authorisation for Bimzelx (bimekizumab), an investigational IL-17A and IL-17F inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
